Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Devon Heroux und 11 weiteren Autor:innen. Beteiligte Einrichtung: Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada; Faculty of Medicine, University of British Columbia, Vancouver…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Copper, Immune Checkpoint Inhibitors, Ionophores. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Breast Cancer Foundation, Canadian Institutes of Health Research, BC Cancer Foundation.
Abstract (Originalsprache)
Copper-binding agents can trigger immunogenic cell death (ICD) and modulate responses to immune checkpoint inhibitors (ICIs), but how tumor copper biology, agent chemistry, and tumor microenvironment shape these effects is unclear. We evaluated diethyldithiocarbamate [Cu(DDC)2] and clioquinol [Cu(CQ)2] in two syngeneic colorectal cancer models with distinct copper handling. In vitro transcriptomic and cytokine profiling showed compound-specific activation of cuproptosis and immune pathways. In vivo, copper accumulation and isotopic fractionation correlated with immune features of the tumor microenvironment, including immune cell infiltration and calreticulin exposure. In CT26 tumors, Cu(CQ)2 transiently enhanced programmed cell death protein 1 (PD-1) blockade, then promoted immune suppression with prolonged dosing. In MC38 tumors, combination therapy showed sustained antagonism or no added benefit. These data indicate that tumor-intrinsic copper handling and ionophore identity jointly determine immune dynamics and therapeutic outcome, and they suggest copper isotopic metrics as candidate biomarkers warranting further evaluation in the context of copper-based strategies with ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: dheroux@bccrc.ca.
- Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada.
- Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada.
- Deeley Research Centre, BC Cancer, Victoria, BC, Canada; Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
- Deeley Research Centre, BC Cancer, Victoria, BC, Canada.
Förderung
- Canadian Breast Cancer Foundation
- Canadian Institutes of Health Research
- BC Cancer Foundation
- NanoMedicines Innovation Network
Zitieren
APA
Heroux, D., Sun, X. X., Zhang, S., Sharifiaghdam, M., Leung, A. W., Farzaneh, S., Milne, K., MacFarlane, T., Di Vito, C., Nelson, B. H., Walsby, C., & Bally, M. B. (2026). Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218281
Vancouver
Heroux D, Sun XX, Zhang S, Sharifiaghdam M, Leung AW, Farzaneh S, et al. Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218281
BibTeX
@article{Heroux2026,
author = {Heroux, Devon and Sun, Xu Xin and Zhang, Sijie and Sharifiaghdam, Maryam and Leung, Ada Wy and Farzaneh, Saeid and Milne, Katy and MacFarlane, Trevor and Di Vito, Chantal and Nelson, Brad H and Walsby, Charles and Bally, Marcel B},
title = {Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218281}
}
EUVIMED